Sage Journals: Discover world-class research

Abstract

Background

Celiac disease is challenging to recognize, predisposing to long diagnostic delay. Currently, associated factors and significance of the delay remain obscure.

Objective

The objective of this article is to investigate associated sociodemographic risk factors and health consequences of diagnostic delay in celiac disease.

Methods

Altogether 611 patients were surveyed at diagnosis and after one year on a gluten-free diet regarding sociodemographic variables, well-being and use of medicines and health care services. Quality of life was measured by a validated Psychological General Well-Being (PGWB) questionnaire. The results were compared between patients with and without delayed (≥3 years) diagnosis.

Results

A total of 332 (54%) individuals reported a delay of ≥3 years. Associated with the delay were being a student or homemaker, but not gender, marital or occupational status, site of diagnosis or place of residence. Patients with the delay also had decreased self-perceived health and poorer PGWB scores compared to those without delay; in anxiety and general health this was seen even on a gluten-free diet. Days of sickness and doctor visits as well as use of drugs for dyspepsia and antidepressants were increased in the delay group both before and after diagnosis.

Conclusion

A delay in celiac disease diagnosis predisposes to reduced well-being and incremental use of medicines and health care services, both before diagnosis and one year after diagnosis.

Keywords

Celiac disease diagnostic delay sociodemographic quality of life health care services

Key summary

Established knowledge on this subject:

Celiac disease is a very common but markedly unrecognized condition.

Median diagnostic delay of the disease is as long as from three to 13 years.

At present, factors underlying and consequences of the delay remain mostly obscure.

New findings of this study:

A diagnostic delay of only three years is associated to decreased quality of life and excess doctor visits, days of sickness and use of pharmaceutical agents before diagnosis.

Many of the detriments associated with the delay may remain overrepresented even during the year after diagnosis.

Being a student or homemaker is associated with reduced risk of delay, whereas no other associations with socioeconomic factors were found.

Introduction

Celiac disease is a gluten-induced immunological disorder with an estimated prevalence of as high as 1%–2% in Western countries.¹ The diverse clinical picture of the disease is a challenge to physicians, and at present approximately 75%–90% of affected individuals remain unrecognized.^2,3 In clinical practice, a mean diagnostic delay of up to even 13 years has been reported.^4–8 Long-term untreated celiac disease predisposes to severe complications such as osteoporosis, infertility and lymphoma,^9–11 and there is also evidence to suggest that in undiagnosed but symptomatic patients incremental use of health care services and pharmaceutical agents is likely.^4,8,12,13

Another concern possibly associated with a delay in diagnosis is poor quality of life, as many untreated celiac patients suffer reduced psychological well-being, which improves on a gluten-free diet.^14–16 Currently it remains unclear what factors are associated with the delay, and whether the delay affects patients’ self-perceived health. In addition, it is not known whether the delay predisposes to long-term increased consumption of medicines and consultations with physicians, which could be prevented by early diagnosis and dietary treatment of celiac disease.

In this prospective study, we investigated a number of patient-centered factors associated with diagnostic delay in celiac disease, and the effect of one year on a gluten-free diet on these. In particular, we aimed to evaluate the role of variable sociodemographic factors in the delay, and whether the delay is associated with individual health burden and increased use of health care services and pharmaceutical agents.

Methods

Participants and study design

The study was conducted in collaboration with the Finnish Celiac Society, which approximately 70% of new celiac disease patients in Finland join soon after diagnosis.¹⁴ During a nationwide enrollment, a structured and validated questionnaire was sent to all new members joining the society in years 2007 and 2008. The patients were diagnosed at all health care levels from primary to tertiary care. Respondents older than 16 years of age with biopsy-proven celiac disease diagnosed within one year were considered eligible and continued in the study. Exclusion criteria were uncertain celiac disease diagnosis and lack of information on the duration of symptoms leading to the diagnosis. A follow-up questionnaire was sent to all participants after one year on a gluten-free diet. No ethical committee review was obtained because this was a questionnaire-based survey. However, informed consent was obtained from all participants after a written explanation of the aims of the study, including considerations regarding ethics and data protection and the anonymous deposition of the questionnaire.

Celiac disease diagnosis was considered delayed (“delay group”) if the disease-related symptoms had lasted at least three years before diagnosis, according to the previously shown median diagnostic delay in Finland.⁸ Specific symptoms leading to celiac disease diagnosis have been defined elsewhere in detail.¹⁴ Participants were further categorized on the basis of place of residence into individuals living in the South/West and those living in the North/East areas of the country, and also into those living either in urban or in rural areas. The South/West region of Finland has a markedly higher population density (41.7 inhabitants/km²) than the North/East (6.4 inhabitants/km²).¹⁷ An urban area was defined as a population center with more than 15,000 inhabitants according to the Finnish Environmental Administration.¹⁸

Questionnaires

The baseline and follow-up questionnaires were designed in cooperation with celiac disease patients and the Finnish Celiac Society. They comprised questions on a variety of sociodemographic aspects and the patients’ perceptions of the impact of the diagnosis on their overall health and well-being. Particular attention was paid to the duration of symptoms before diagnosis, occupational and working position, place of residence, site of first suspicion and diagnosis of celiac disease (primary, secondary or tertiary care), and self-rated health, concern for health, burden of symptoms and reaction to the celiac disease diagnosis both at the time of diagnosis and after one year on a gluten-free diet. Self-estimated health was rated on a four-point Likert scale as excellent, good, fair or poor; in analysis excellent and good were combined. Concern for personal health and burden of symptoms ranged from “not at all” to “extremely” on a three-point Likert scale. The participants also reported the number of all-cause visits to health care providers, consumption of pharmaceutical agents and days of absence from work during the year before diagnosis and in the first year on a gluten-free diet. Moreover, patients were asked about adherence to the gluten-free diet after one year on the diet.

Health-related quality of life

In addition to the above survey, self-estimated quality of life was measured by the structural Psychological General Well-Being Questionnaire (PGWB) both at diagnosis and after one year of a gluten-free diet. PGWB is a well-validated and widely used questionnaire in general and also in celiac disease research.^15,16,19 It consists of 22 items, each using a six-grade Likert scale, with higher scores indicating better psychological well-being. The questionnaire is further subdivided into six subdimensions, each containing three to five separate items: anxiety, depression, well-being, self-control, general health and vitality. The total PGWB score is the sum of all 22 items and may thus range from 22 to 132 points.

Statistics

The feasibility of the study questions was pretested by a group of celiac disease patients as previously described in detail.²⁰ Briefly, for test-retest reliability, 11 treated patients repeated the questionnaire one week after the first contact and the intraclass correlation coefficient was measured. The kappa values ranged from 0.84 to 1.00, being thus considered excellent (> 0.70). Statistical analysis was carried out using the Statistical Package for the Social Sciences Statistics, version 20.0 (IBM, Armonk, NY, USA). Binary logistic regression analysis was used to identify category factors associated with diagnostic delay. The results are shown as odds ratios (ORs) with 95% confidence interval (CI). A p value ≤ 0.05 was considered significant. Quantitative data were analyzed by independent-samples t test for normally distributed variables and by Mann-Whitney U test for skewed variables. The use of pharmaceuticals was divided into any use or no use of certain medicines and analyzed by Chi-square test. In order to make the results more comprehensive, both range and medians with quartiles are shown in Table 4. All data were blindly coded before statistical analysis.

Table 1.

Association between diagnostic delay^a and sociodemographic characteristics at diagnosis in 611 adults with celiac disease.

	n	Delay, %	Odds ratio	95% CI	p value
Gender
Male	262	56	1
Female	467	49	0.82	0.93–1.97	0.232
Marital status
Married/with partner	460	55	1
Single	151	53	0.93	0.64–1.34	0.700
Occupational status
Employed	388	56	1
Student or homemaker	56	36	0.43	0.24–0.78	0.005
Unemployed	15	73	2.14	0.67–6.85	0.198
Retired	138	53	0.88	0.59–1.29	0.876
Position at workplace
High	156	60	1
Middle	145	55	0.83	0.53–1.32	0.436
Low	279	52	0.74	0.50–1.11	0.143
Geographical residence
North and East^b	159	52	1
South and West^c	452	55	1.16	0.81–1.67	0.416
Urban or rural residence
Urban	351	56	1
Rural	260	52	0.82	0.60–1.13	0.232
First suspicion of disease
Secondary/tertiary care	75	51	1
Primary care	289	51	0.99	0.60–1.65	0.982
Oneself, friend, family	214	58	1.37	0.81–2.32	0.245
Site of diagnosis
Secondary/tertiary care	283	52	1
Primary care	325	56	1.16	0.84–1.60	0.361

Celiac disease-related symptoms for three years or more before diagnosis. ^bPopulation density 6.4/km². ^cPopulation density 41.7/km².

CI: confidence interval.

Results

Altogether 1062 (57%) of the 1864 new members joining the Celiac Society during the study period responded. Of these, 451 were excluded: 157 as not being diagnosed within one year, 132 for being younger than 16 years of age, 89 for a lack of information regarding the duration of symptoms or otherwise substantially missing data and 73 owing to unclear celiac disease diagnosis. Of the 611 eligible individuals, 559 (91%) also completed the follow-up questionnaire. Seventy-six percent of the final study cohort were women.

The median duration of symptoms before celiac disease diagnosis was three (range 0–50) years and in 332 (54%) cases diagnosis was delayed by at least three years. Median age at diagnosis was 50 (16–75) years in patients with a delay and 48 (17–82) years in those without a delay (p = 0.363).

Of the various sociodemographic characteristics, being a student or homemaker was associated with reduced risk of diagnostic delay compared with being employed (Table 1). In contrast, gender, marital or occupational status, position at workplace, geographical residence and site of first suspicion or eventual diagnosis of celiac disease had no association with the risk of delay (Table 1).

Table 2.

Associations between diagnostic delay^a and self-rated perceptions of health at diagnosis and one year after diagnosis in 611 adults with celiac disease.

	n	Delay %	Odds ratio	95% CI	p value
At diagnosis
Self-perceived health
Good	242	47	1
Fair	278	59	1.64	1.16–2.33	0.005
Poor	87	60	1.70	1.03–2.79	0.037
Concern about health
Not at all	55	29	1
Moderate	436	55	2.99	1.62–5.50	<0.001
Extreme	117	63	4.20	2.10–8.39	<0.001
Burden of symptoms
Not at all	44	32	1
Moderate	287	52	2.31	1.18–4.55	0.015
Extreme	259	62	3.58	1.81–7.08	<0.001
Reaction to the diagnosis
Upset or confused	300	49	1
Relieved	291	60	1.55	1.12–2.15	0.008
One year after diagnosis
Self-perceived health
Good	411	53	1
Fair	130	58	1.22	0.82–1.82	0.329
Poor	17	53	1.01	0.38–2.66	0.990
Concern about health
Not at all	164	45	1
Moderate	371	58	1.70	1.17–2.26	0.005
Extreme	24	50	1.22	0.52–2.87	0.654

Celiac disease-related symptoms for three years or more before diagnosis.

CI: confidence interval.

All 559 individuals who returned the follow-up questionnaires were on a gluten-free diet, but 64 (11%) reported occasional lapses. On the diet the symptoms disappeared completely in 130 (23%), were alleviated in 337 (60%), remained unchanged in 71 (13%) and increased in three (0.5%) people. The likelihood of symptoms persisting on a gluten-free diet was increased in those with diagnostic delay (OR 1.61, 95% CI 1.08–2.42, p = 0.022).

Diagnostic delay was associated with the risk of poor or only fair self-estimated health and concern about health at celiac disease diagnosis (Table 2). After one year on a gluten-free diet, there was no longer a difference between the groups in self-perceived health, but concern about health remained higher in patients with the delay. Further, these individuals more often reported a moderate or extreme burden of symptoms at diagnosis and experienced feeling relief (compared to upset or confused) after the diagnosis in comparison to patients with no delay (Table 2).

Table 3.

Psychological General Well-Being scores of 592 celiac disease patients^a at diagnosis and one year after diagnosis, categorized by length of diagnostic delay.

	Delay ≥ 3 years	Delay < 3 years
	Mean (95% CI)	Mean (95% CI)	p value^b
At diagnosis
Total	87.1 (84.9–89.4)	93.6 (91.2–96.0)	<0.001
Anxiety	19.9 (19.3–20.5)	21.6. (20.9–22.2)	0.003
Depressed mood	14.2 (13.9–14.5)	14.9 (14.5–15.2)	0.001
Positive well-being	14.4 (14.0–14.9)	15.4 (14.9–15.9)	<0.001
Self-control	13.2 (12.8–13.5)	14.1 (13.7–14.4)	<0.001
General health	10.8 (10.5–11.1)	11.9 (11.6–12.3)	<0.001
Vitality	10.9 (10.5–11.2)	11.9 (11.5–12.3)	<0.001
One year after diagnosis
Total	101.6 (99.6–103.5)	103.5 (101.5–105.6)	0.132
Anxiety	23.3. (22.8–23.8)	24.0 (23.5–24.5)	0.048
Depressed mood	16.0 (15.7–16.3)	16.2. (16.0–16.5)	0.220
Positive well-being	16.7 (16.3–17.1)	17.1 (16.6–17.4)	0.339
Self-control	14.9 (14.7–15.2)	15.0 (14.7–15.3)	0.628
General health	13.0 (12.7–13.4)	13.6 (13.3–14.0)	0.009
Vitality	12.8 (12.5–13.2)	13.2 (12.8–13.5)	0.070

592 patients at diagnosis and 580 after one year. ^bIndependent-samples t test.

CI: confidence interval.

PGWB total and all subscores were significantly lower at diagnosis in patients with delayed diagnosis compared to those without (Table 3). On dietary treatment, the scores improved in both groups, but anxiety and general health scores remained lower in the delay group (Table 3).

Table 4.

Use of health care services in the year prior to and following diagnosis in 611 celiac disease patients, categorized by length of diagnostic delay.

	Delay ≥ 3 years		Delay < 3 years
	Median (Q1,Q3)	Range	Median (Q1, Q3)	Range	p value^a
Before diagnosis
Doctor visits^b	3 (1, 5)	0–31	2 (1, 4)	0–30	0.002
Days of sickness	0 (0, 5)	0–200	0 (0, 3)	0–180	0.020
After diagnosis
Doctor visits^b	2 (1, 4)	0–20	1 (0, 3)	0–15	<0.001
Days of sickness	0 (0, 6)	0–356	0 (0, 4)	0–365	0.021

Mann-Whitney U test. ^bIn primary care.

Q1, Q3: lower and upper quartiles; CI: confidence interval.

The numbers of outpatient visits in primary health care and days of sickness during the year prior to celiac disease diagnosis were higher in individuals with diagnostic delay compared to those without (Table 4). The frequency of visits decreased in both groups during the year following diagnosis, but the difference remained significant. In contrast to outpatient visits, the number of days of sickness increased in both groups on a gluten-free diet (Table 4).

The proportion of patients using analgesics, drugs for dyspepsia and antidepressants was increased in patients with diagnostic delay compared to those without during the year before diagnosis, and the difference in the two latter remedies remained significant on a gluten-free diet (Table 5). There was a similar but nonsignificant trend with antibiotics in the year before diagnosis (Table 5). Comparable differences between the delay group and controls were seen when the use of pharmaceutical agents was analyzed according to amount of pills per month (data not shown).

Table 5.

Proportion of patients using pharmaceutical agents in the year prior to and following diagnosis in 611 celiac disease patients, categorized by length of diagnostic delay.

	Delay ≥ 3 years	Delay < 3 years
	%	%
	n = 330	n = 279	p value^a
Before diagnosis
Analgesics	69.4	60.9	0.029
Dyspepsia drugs	34.1	20.1	<0.001
Antidepressants	11.0	5.4	0.014
Sleeping pills	13.9	10.8	0.236
Antibiotics	34.9	27.6	0.055
Other^b	51.8	48.2	0.308
After diagnosis	n = 301	n = 258
Analgesics	68.1	67.4	0.867
Dyspepsia drugs	23.6	14.0	0.004
Antidepressants	9.7	5.0	0.039
Sleeping pills	14.0	11.2	0.337
Antibiotics	28.9	26.5	0.520
Other^b	55.5	56.6	0.793

Chi-square test.

Vitamins, micronutrients, herbal products.

Discussion

Our main finding was that as little as three years’ diagnostic delay in celiac disease is associated with reduced health and well-being and increased use of health care and medicines. In fact, many of these detriments remained overrepresented in the delay group even during the year after diagnosis. Since in many countries the median delay is as high as 9–13 years,^4–7 the morbidity observed here in patients with a substantially shorter period is alarming. Although part of these problems may eventually be alleviated on a gluten-free diet, it seems that a considerable number of celiac patients suffer from an excess health and economic burden avoidable by earlier diagnosis.

One of the key findings here was the reduced self-perceived health and psychological well-being in patients with a diagnostic delay. This is in accord with a previous Swedish study likewise showing poorer quality of life at diagnosis in those with a long delay.⁷ Here, some of these important clinical outcomes remained poorer even after one year on a gluten-free diet, indicating that recovery from the psychological burden associated with long-term unrecognized celiac disease takes some time. Moreover, although the matter remains somewhat controversial,^15,21 there is previous evidence that a subgroup of patients may continue to suffer from persistent poor health and mental problems even after years on a gluten-free diet.^7,16 It is therefore essential that physicians and other health care professionals devote particular attention and support to those with a markedly delayed celiac disease diagnosis.

Somewhat surprisingly, we found no association between different socioeconomic factors and diagnostic delay except for a lower risk in students and homemakers compared to those who were employed. The lack of other associations might be related to the long-term political goal to reduce inequalities in health and health care in Finland.²² Here, inexpensive and easily accessible public health care diagnoses and treats the great majority (in the present study 89%) of celiac disease patients. Because of the differences in health care systems, some caution is needed before extrapolating our findings to other countries. For example, more variability exists in terms of health care accessibility in the United States, where low income has been shown to be a major barrier to celiac disease diagnosis.²³ Significant regional and socioeconomic variation in the prevalence of celiac disease has also been observed in the United Kingdom, possibly reflecting disparities in health-seeking behavior and/or access to correct diagnostic pathways.²⁴ The somewhat counterintuitive lower risk of delay in students and homemakers noted here might be explained by the well-organized student health care and maternity clinics in Finland.^25,26 Although there are no other similar studies, Vavricka and colleagues²⁷ have previously shown age younger than 30 years, the typical age for students and homemakers, to be associated with reduced risk of diagnostic delay.

Neither place of residence nor level of health care at which the celiac disease diagnosis was made was associated with the risk of diagnostic delay. This is compatible with our previous findings in patients with a delay of 10 years diagnosed mostly in the area of one tertiary center,²⁸ whereas the earlier mentioned British study reported significant regional differences in the diagnostic delay.²⁴ The low regional variation in Finland is very likely affected by the frequently updated nationwide Current Care Guidelines for celiac disease.²⁹ The guidelines aim to increase awareness and diagnostic efficacy in celiac disease particularly in primary care.

As a result of this decentralization the prevalence of diagnosed celiac disease in Finland is among the highest in the world.^28,30 There are no studies from other countries evaluating the effect of such a reorganization of celiac disease diagnostics, but the issue has been investigated for instance in inflammatory bowel disease and chronic lung diseases, with somewhat less promising results.^31,32 We believe that primary care diagnostics can be very successful, but only if combined with practical diagnostic tools and continuous education of physicians.

Patients in the delay group reported more primary health care visits and days of sickness both in the year prior to and following the diagnosis. One reason leading to excess visits and ill health could be the often vague and unspecific symptoms not being recognized as celiac disease.³³ The higher use of health care even after the diagnosis might be related to our previous observation that diagnostic delay predisposes individuals to persistent symptoms on a gluten-free diet.¹⁶ The increased number of days of sickness probably occurs for the same reasons as the excess health care visits. Interestingly, a similar association between delayed diagnosis and increased work absence has been reported in endometriosis patients,³⁴ further demonstrating difficulties encountered in cases of chronic diseases with a diverse clinical picture. The increased work absence in both study groups in the year following diagnosis can be explained for example by a severe infection season.

There was also incremental use of analgesics, antidepressants and medicines for dyspepsia in the delay group in the year prior to the diagnosis. Previous studies have already shown excessive use of pharmaceuticals preceding celiac diagnosis,^8,35 and this problem would appear to be further aggravated by delay. We could not trace the indications for these drugs, but they might have been prescribed for example in an attempt to ameliorate persistent gastrointestinal and depressive symptoms caused by unrecognized celiac disease.^13,36 A parallel association between delay and excessive analgesic use before diagnosis has again been observed in endometriosis patients.³⁷ In line with the lower quality of life and excess health care visits, the increased drug use continued even after the diagnosis. Besides slow resolution of symptoms, this might be due to patients’ reluctance to discontinue drugs they have used with some benefits perhaps for several years.

The main strengths of the study were its prospective design, the large nationwide patient cohort, validated questionnaires and broad range of relevant study outcomes. There was also an excellent response rate in the follow-up survey. On the other hand, questionnaire-based studies are prone to overrepresentation of healthy individuals who feel well, the risk of which is further aggravated by participants being members of celiac societies. It is also noteworthy that, although the treatment response was followed prospectively, outcomes and duration of symptoms before diagnosis were assessed retrospectively and are thus prone to recall bias. However, a recall period covering a maximum of one year in self-reported use of health care services and pharmaceutical agents has previously been shown to be reliable.³⁸ The fact that the patients were enrolled almost 10 years ago might in theory have an effect, but there have been no major changes in our health care system or celiac disease diagnostics, and we believe that the results are still representative. Finally, because of a lack of original patient records, we were unable to verify the self-reported medical information including celiac disease diagnosis, and to evaluate the possible impact of different comorbidities on results.

Conclusions

We found even a relatively short diagnostic delay in celiac disease to be associated with increased health burden both at the individual and society level. Improved awareness of the diversity of the disease among physicians and at-risk group screening could be an effective means to reduce the delay at the population level.

Footnotes

Declaration of conflicting interests

None declared.

Ethics approval

No ethical committee review was obtained because this was a questionnaire-based survey.

Funding

This work was supported by the Competitive Research Funding of Tampere University Hospital, the Sigrid Juselius Foundation, the Yrjö Jahnsson Foundation and the Foundation for Pediatric Research.

Informed consent

Informed consent was obtained from all participants after a written explanation of the aims of the study, including considerations regarding ethics and data protection and the anonymous deposition of the questionnaire.

References

Mustalahti

Catassi

Reunanen

et al.

Coeliac EU Cluster, Project Epidemiology. The prevalence of celiac disease in Europe: Results of a centralized, international mass screening project. Ann Med 2010; 42: 587–595.

West

Logan

Hill

et al.

Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003; 52: 960–965.

Rubio-Tapia

Ludvigsson

Brantner

et al.

The prevalence of celiac disease in the United States. Am J Gastroenterol 2012; 107: 1538–1544.

Cranney

Zarkadas

Graham

et al.

The Canadian Celiac Health Survey. Dig Dis Sci 2007; 52: 1087–1095.

Gray

Papanicolas

. Impact of symptoms on quality of life before and after diagnosis of coeliac disease: Results from a UK population survey. BMC Health Serv Res 2010; 10: 105–105.

Green

PHR

Stavropoulos

Panagi

et al.

Characteristics of adult celiac disease in the USA: Results of a national survey. Am J Gastroenterol 2001; 96: 126–131.

Norström

Lindholm

Sandström

et al.

Delay to celiac disease diagnosis and its implications for health-related quality of life. BMC Gastroenterol 2011; 11: 118–118.

Ukkola

Kurppa

Collin

et al.

Use of health care services and pharmaceutical agents in coeliac disease: A prospective nationwide study. BMC Gastroenterol 2012; 12: 136–136.

Gasbarrini

Torre

Trivellini

et al.

Recurrent spontaneous abortion and intrauterine fetal growth retardation as symptoms of coeliac disease. Lancet 2000; 356: 399–400.

10.

Corazza

Di Sario

Cecchetti

et al.

Bone mass and metabolism in patients with celiac disease. Gastroenterology 1995; 109: 122–128.

11.

Holmes

Prior

Lane

et al.

Malignancy in coeliac disease—effect of a gluten free diet. Gut 1989; 30: 333–338.

12.

Dickey

McConnell

. How many hospital visits does it take before celiac sprue is diagnosed? J Clin Gastroenterol 1996; 23: 21–23.

13.

Card

Siffledeen

West

et al.

An excess of prior irritable bowel syndrome diagnoses or treatments in celiac disease: Evidence of diagnostic delay. Scand J Gastroenterol 2013; 48: 801–807.

14.

Ukkola

Mäki

Kurppa

et al.

Diet improves perception of health and well-being in symptomatic, but not asymptomatic, patients with celiac disease. Clin Gastroenterol Hepatol 2011; 9: 118–123.

15.

Roos

Karner

Hallert

. Psychological well-being of adult coeliac patients treated for 10 years. Dig Liver Dis 2006; 38: 177–180.

16.

Paarlahti

Kurppa

Ukkola

et al.

Predictors of persistent symptoms and reduced quality of life in treated coeliac disease patients: A large cross-sectional study. BMC Gastroenterol 2013; 13: 75–75.

17.

Statistics Finland. Population density by area, http://tilastokeskus.fi/til/vaerak/tau.html (2014, accessed 14 September 2017).

18.

Finland’s Environmental Administration. Urban-rural classification, http://www.ymparisto.fi/kaupunkimaaseutuluokitus (2014, accessed 14 September 2017).

19.

Dimenas

Carlsson

Glise

et al.

Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8–13.

20.

Ukkola

Mäki

Kurppa

et al.

Changes in body mass index on a gluten-free diet in coeliac disease: A nationwide study. Eur J Intern Med 2012; 23: 384–388.

21.

Zingone

Swift

Card

et al.

Psychological morbidity of celiac disease: A review of the literature. United European Gastroenterol J 2015; 3: 136–145.

22.

Palosuo

Sihto

. Reducing health inequalities in Finland: Progressing or regressing? Nordic Welfare Research 2016; 1: 55–64.

23.

Hafner-Eaton

. Physician utilization disparities between the uninsured and insured. Comparisons of the chronically ill, acutely ill, and well nonelderly populations. JAMA 1993; 269: 787–792.

24.

West

Fleming

Tata

et al.

Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: Population-based study. Am J Gastroenterol 2014; 109: 757–768.

25.

Ministry of Social Affairs and Health Finland. Maternity and Child Health Clinics, http://stm.fi/en/maternity-and-child-health-clinics (accessed 14 September 2017).

26.

Kunttu K. Student health survey 2012: A national survey among Finnish university students 2012, http://www.yths.fi/filebank/2263-KOTT2012_in_English.pdf (2012, accessed 14 September 2017).

27.

Vavricka

Vadasz

Stotz

et al.

Celiac disease diagnosis still significantly delayed—Doctor’s but not patients’ delay responsive for the increased total delay in women. Dig Liver Dis 2016; 48: 1148–1154.

28.

Fuchs

Kurppa

Huhtala

et al.

Factors associated with long diagnostic delay in celiac disease. Scand J Gastroenterol 2014; 49: 1304–1310.

29.

Finnish Medical Society Duodecim and the Finnish Society of Gastroenterology. Current care guideline: Coeliac disease, http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=hoi08001 (2017, accessed 14 September 2017).

30.

Virta

Kaukinen

Collin

. Incidence and prevalence of diagnosed coeliac disease in Finland: Results of effective case finding in adults. Scand J Gastroenterol 2009; 44: 933–938.

31.

Izquierdo

Martin

de Lucas

et al.

Misdiagnosis of patients receiving inhaled therapies in primary care. Int J Chron Obstruct Pulmon Dis 2010; 5: 241–249.

32.

Vavricka

Spigaglia

Rogler

et al.

Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 496–505.

33.

Stasi

Marafini

Caruso

et al.

Frequency and cause of persistent symptoms in celiac disease patients on a long-term gluten-free diet. J Clin Gastroenterol 2016; 50: 239–243.

34.

Nnoaham

Hummelshoj

Webster

et al.

Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries. Fertil Steril 2011; 96: 366–373.e8.

35.

Mattila

Kurppa

Ukkola

et al.

Burden of illness and use of health care services before and after celiac disease diagnosis in children. J Pediatr Gastroenterol Nutr 2013; 57: 53–56.

36.

Smith

Gerdes

. Meta-analysis on anxiety and depression in adult celiac disease. Acta Psychiatr Scand 2012; 125: 189–193.

37.

Staal

van der Zanden

Nap

. Diagnostic delay of endometriosis in the Netherlands. Gynecol Obstet Invest 2016; 81: 321–324.

38.

Longobardi

Walker

Graff

et al.

Health service utilization in IBD: Comparison of self-report and administrative data. BMC Health Serv Res 2011; 11: 137–137.

Delayed celiac disease diagnosis predisposes to reduced quality of life and incremental use of health care services and medicines: A prospective nationwide study

Abstract

Background

Objective

Methods

Results

Conclusion

Keywords

Key summary

Introduction

Methods

Participants and study design

Questionnaires

Health-related quality of life

Statistics

Results

Discussion

Conclusions

Footnotes

Declaration of conflicting interests

Ethics approval

Funding

Informed consent

References